Albert, French dermatologist, 1880-1956. See: Sézary cell, Sézary erythroderma, Sézary syndrome.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sezary syndrome.
The concept of primary cutaneous [CD4.sup.+] small/medium T-cell lymphoma (PC-SMTCL) began in the early 1990s when the updated Kiel classification system (1,2) was applied to primary cutaneous T-cell lymphomas that did not meet criteria for mycosis fungoides (MF) or Sezary syndrome.
[ClickPress, Tue Jan 07 2014] GlobalData's clinical trial report, "Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario.
The various types of malignancy associated with PEO are T and B cell lymphoma, leukemia, adenocarcinoma of gut and cutaneous T cell lymphoma.1,4,5 There are reports of PEO associated with AIDS and drug ingestion.6,7 The association of PEO with malignancy and laboratory features like circulating Sezary cells, hypereosinophilia and raised IgE levels point towards the heterogenous nature of this entity.8 When associated with lymphoma, the dermatosis may appear several years before the diagnosis of malignancy or vice versa, so the association of two pathologies in a possible nosological overview has been stressed.9
(%) Lymphoblastic leukemia 167 (33.4) Myeloid leukemia 118 (23.6) Chronic lymphocytic leukemia 99 (19.8) Plasma cell myeloma 91 (18.2) Other (a) 10 (0.2) (a) Other includes textual answers including all lymphomas, B cell lymphoma, T cell lymphoma, non-Hodgkin lymphoma, hairy cell leukemia, Sezary syndrome, myelodyplastic syndrome, and acute leukemias.
In the case of our patient, the diagnosis of Sezary syndrome was excluded because laboratory tests did not confirm the pres-ence of Sezary cells in the peripheral blood smear, only lympho-cytes with a similar morphology, whose numbers were continu-ally oscillating.
Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
According to the company, the trial's primary endpoint is to assess local and distant response rate following treatment of cutaneous T-cell lymphoma lesions (mycosis fungoides or Sezary patients) with a DNA-based cytokine coded for the immune stimulating agent interleukin-12 (DNA IL-12) and electroporation.
[ClickPress, Thu Apr 09 2015] GlobalData's clinical trial report, "Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario.
The peripheral blood smear should also be scanned for Sezary cells or other atypical lymphocytes because of the frequent association of secondary eosinophilia with T-cell neoplasms.